Fisher Wallace Laboratories

Fisher Wallace manufactures and markets wearable medical devices for the treatment of depression, anxiety and insomnia.

$1500+ | 42% discount on the purchase of a Fisher Wallace device $5,000+ | Above + 2% bonus shares $10,000+ | Above + 3% bonus shares $20,000+ | Above + 5% bonus shares

An FDA-Cleared, clinically validated solution for depression, anxiety and insomnia with over 50,000 patients and 10,000 prescribers in the United States $4.7 Million net revenue in 2018 with total lifetime revenue of $23.3 Million Named an INC 5000 fastest growing company with OTC approval in Europe, Canada, Mexico and Brazil, and recently obtained Medicaid approval in Maine (MaineCare)

StartEngine Platform Fees: 3.5%, 

Marketing: 50.5%, 

Research & Development: 46.0

Kelly Roman Co-Founder & CEO & Director For the past decade, Kelly Roman has helped lead the fields of neuromodulation product development, regulatory affairs, healthcare marketing and clinical trial strategy. Prior to co-founding Fisher Wallace, Kelly graduated from Harvard and served as an award-winning executive in the digital advertising and SaaS industries. He currently serves on the boards of two charter high schools in New York City. Charles Fisher Co-Founder & Chairman & Director Charles “Chip” Fisher grew up in the electronics business before helping pioneer the neuromodulation industry - his father, Avery Fisher, founded Fisher Radio (later named Fisher Electronics). After graduating from Harvard and serving as a sales executive at IBM, Chip acquired the original intellectual property to the Fisher Wallace Stimulator and is the company’s largest shareholder - and recent TEDx contributor.

Security Name: Class B Non-Voting Stock

$2.50 per share